Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

September 15, 2016

Study Completion Date

September 15, 2016

Conditions
OsteoarthritisPain
Interventions
DRUG

Placebo

Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.

DRUG

Fulranumab 1 mg

Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

DRUG

Fulranumab 3 mg

Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.

Trial Locations (32)

Unknown

Phoenix

Costa Mesa

Laguna Hills

Lakewood

Northridge

Santa Clarita

Thousand Oaks

Boynton Beach

Lake Clarke Shores

Miami

Atlanta

Chicago

Wichita

Bay City

Caro

Grand Rapids

Somerset

Greenville

Charleston

Memphis

Bedford

Cypress

Houston

Waxahachie

Riverton

Norfolk

Elblag

A Coruña

Barcelona

Mérida

Santiago de Compostela

Stourton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02336698 - Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 | Biotech Hunter | Biotech Hunter